Hillel Cohen, PhD, of Sandoz on Increasing Patient Access to Biosimilars Through Stakeholder Engagement and Education

Thursday October 24, 2019

Sandoz, Inc. Executive Director of Scientific Affairs Hillel Cohen joins us to talk about the future of biosimilars in the United States. Accessibility begins with educating patients, providers and payers on biosimilars, interchangeability and the safety and effectiveness of these more cost-effective treatments.

In this video, Dr. Cohen discusses:

  • What a biologic drug is, and why patients can expect the same efficacy and safety that they see in a biologic in a biosimilar.
  • Variability in biosimilars and the importance and emphasis the FDA places on ensuring both biologics and biosimilars have a robust safety profile for patients.
  • The birth of biosimilars in the U.S. and the FDA approval process for a biosimilar drug.
  • The interchangeability designation for biosimilars and the rigorous process that a biosimilar must complete in order to achieve such a designation.
  • The barriers to patient uptake of biosimilars, including the current naming convention.
  • Patient access and the future of biosimilars.

This video was created as part of the first Member Spotlight Series — in-depth content featuring experts from the Biosimilars Council sharing their unique experience and perspective on issues impacting the emerging biosimilars market.

Related Resources:

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending. Additional information is available at www.accessiblemeds.org.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.